NCT03829410 is a Phase 1, PHASE2 clinical trial of Onvansertib in Metastatic Colorectal Cancer, sponsored by Cardiff Oncology.

Who is sponsoring NCT03829410?

NCT03829410 is sponsored by Cardiff Oncology.

What drugs are being tested in NCT03829410?

Interventions in NCT03829410: Onvansertib, Bevacizumab, FOLFIRI.

What condition does NCT03829410 study?

NCT03829410 studies Metastatic Colorectal Cancer, KRAS Gene Mutation.

Is NCT03829410 still recruiting?

NCT03829410 is currently completed. Last updated 4 March 2025.

Are results published for NCT03829410?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2025-03-04 · How we verify

NCT03829410

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Onvansertib in Combination With FOLFIRI and Bevacizumab for Second Line Treatment of Metastatic Colorectal Cancer Patients With a KRAS Mutation

Completed Phase 1, PHASE2 Results posted Last updated 4 March 2025

What this trial tests

Phase 1, PHASE2 trial testing Onvansertib in Metastatic Colorectal Cancer in 68 participants. Completed in 29 January 2024.

Timeline

24 June 2019

Primary endpoint
29 January 2024

29 January 2024

Quick facts

Lead sponsor	Cardiff Oncology
Phase	Phase 1, PHASE2
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	sequential
Masking	none
Primary purpose	treatment
Enrollment	68
Start date	24 June 2019
Primary completion	29 January 2024
Estimated completion	29 January 2024
Sites	7 locations across United States

Drugs / interventions tested

Onvansertib (onvansertib) — full drug profile →
Bevacizumab (Bevacizumab-Bvzr) — full drug profile →
FOLFIRI (folfiri) — full drug profile →

Conditions studied

Metastatic Colorectal Cancer — all drugs for Metastatic Colorectal Cancer →
KRAS Gene Mutation — all drugs for KRAS Gene Mutation →

Sponsor

Cardiff Oncology — full company profile →

Who can join

18 and older, any sex, with Metastatic Colorectal Cancer or KRAS Gene Mutation. Patients with the condition only — healthy volunteers not accepted.

Results — posted to ClinicalTrials.gov

Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.

Phase 1b: Number of Participants With Dose-limiting Toxicities (DLTs) Primary · Up to Day 28

DLTs were defined as a Grade 4 hematologic adverse events (AEs), Grade ≥ 3 non-hematologic AEs that were considered related to the study drug and that did not resolve within 14 days following presentation with standard management and care, Grade ≥ 3 thrombocytopenia with bleeding, neutropenic fever, any death not clearly due to the underlying disease or extraneous causes, or any change in liver function that met Hy's Law criteria of a DLT.

Group	Value	95% CI
Phase 1b: Onvansertib 12 mg/m^2	1
Phase 1b: Onvansertib 15 mg/m^2	1
Phase 1b: Onvansertib 18 mg/m^2	3

Phase 1b: Number of Participants With Treatment-emergent Adverse Events (TEAEs) Primary · Up to a maximum of 81 weeks

AEs were defined as any untoward medical occurrence associated with the use of a drug in humans. TEAEs are defined as any AE that started on or after the first day of study treatment and within 30 days of the last administration of study treatment, or that worsened on or after the first day of study treatment. AE severity was graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 on a scale from Grade 1 (mild) to Grade 5 (death). An AE was considered "serious" if it resulted in death, life-threatening AE, hospitalization or prolonga

Any TEAE

Group	Value	95% CI
Phase 1b: Onvansertib 12 mg/m^2	9
Phase 1b: Onvansertib 15 mg/m^2	7
Phase 1b: Onvansertib 18 mg/m^2	6

Any TEAE Related to Onvansertib

Group	Value	95% CI
Phase 1b: Onvansertib 12 mg/m^2	8
Phase 1b: Onvansertib 15 mg/m^2	7
Phase 1b: Onvansertib 18 mg/m^2	4

Any TEAE CTCAE Grade ≥3

Group	Value	95% CI
Phase 1b: Onvansertib 12 mg/m^2	7
Phase 1b: Onvansertib 15 mg/m^2	6
Phase 1b: Onvansertib 18 mg/m^2	4

Any TEAE CTCAE Grade ≥3 Related to Onvansertib

Group	Value	95% CI
Phase 1b: Onvansertib 12 mg/m^2	4
Phase 1b: Onvansertib 15 mg/m^2	1
Phase 1b: Onvansertib 18 mg/m^2	1

Any Serious TEAE

Group	Value	95% CI
Phase 1b: Onvansertib 12 mg/m^2	2
Phase 1b: Onvansertib 15 mg/m^2	3
Phase 1b: Onvansertib 18 mg/m^2	1

Any Serious TEAE Related to Onvansertib

Group	Value	95% CI
Phase 1b: Onvansertib 12 mg/m^2	0
Phase 1b: Onvansertib 15 mg/m^2	0
Phase 1b: Onvansertib 18 mg/m^2	0

All-Treated Analysis Set: Objective Response Rate (ORR) Primary · Up to a maximum of 131 weeks

ORR was defined as the percentage of participants documented to have a confirmed complete response (CR) or partial response (PR) using the Response Evaluation Criteria In Solid Tumors Version 1.1 (RECIST v1.1). Two-sided 95% confidence interval (CI) was calculated using the exact binomial Clopper-Pearson method. CR: disappearance of all target and non-target lesions. Any pathological lymph nodes (whether target or non-target) must have had a reduction in short axis to \< 10 mm. All lymph nodes must have been non-pathological in size (\< 10mm short axis). PR: at least a 30% decrease in the su

Group	Value	95% CI
Phase 1b: Onvansertib 15 mg/m^2	42.9	9.9 – 81.6
Phase 2 Part 1: Onvansertib 15 mg/m^2	27.3	13.3 – 45.5
Phase 2 Part 2: Onvansertib 15 mg/m^2	15.4	1.9 – 45.4
Phase 1b and 2 Total: Onvansertib 15 mg/m^2	26.4	15.3 – 40.3

Phase 2: Number of Participants With TEAEs Secondary · Up to a maximum of 131 weeks

AEs were defined as any untoward medical occurrence associated with the use of a drug in humans. TEAEs are defined as any AE that started on or after the first day of study treatment and within 30 days of the last administration of study treatment, or that worsened on or after the first day of study treatment. AE severity was graded according to the CTCAE version 5.0 on a scale from Grade 1 (mild) to Grade 5 (death). An AE was considered "serious" if it resulted in death, life-threatening AE, hospitalization or prolongation of hospitalization, persistent or significant incapacity, or congenita

Any TEAE

Group	Value	95% CI
Phase 2: Onvansertib 15 mg/m^2	46

Any TEAE Related to Onvansertib

Group	Value	95% CI
Phase 2: Onvansertib 15 mg/m^2	26

Any TEAE CTCAE Grade ≥3

Group	Value	95% CI
Phase 2: Onvansertib 15 mg/m^2	32

Any TEAE CTCAE Grade ≥3 Related to Onvansertib

Group	Value	95% CI
Phase 2: Onvansertib 15 mg/m^2	8

Any Serious TEAE

Group	Value	95% CI
Phase 2: Onvansertib 15 mg/m^2	17

Any Serious TEAE Related to Onvansertib

Group	Value	95% CI
Phase 2: Onvansertib 15 mg/m^2	1

All-Treated Analysis Set: Disease Control Rate (DCR) Secondary · Up to a maximum of 131 weeks

DCR was defined as the percentage of participants documented to have a confirmed CR, PR or stable disease (SD) using the RECIST v1.1. Two-sided 95% CI was calculated using the exact binomial Clopper-Pearson method. CR: disappearance of all target and non-target lesions. Any pathological lymph nodes (whether target or non-target) must have had a reduction in short axis to \< 10 mm. All lymph nodes must have been non-pathological in size (\< 10mm short axis). PR: at least a 30% decrease in the sum of diameters of target lesions, taking as reference the Baseline sum diameters. SD: neither suff

Group	Value	95% CI
Phase 1b: Onvansertib 15 mg/m^2	100	59.0 – 100.0
Phase 2 Part 1: Onvansertib 15 mg/m^2	90.9	75.7 – 98.1
Phase 2 Part 2: Onvansertib 15 mg/m^2	92.3	64.0 – 99.8
Phase 1b and 2 Total: Onvansertib 15 mg/m^2	92.5	81.8 – 97.9

All-Treated Analysis Set: Progression-free Survival (PFS) Secondary · Up to a maximum of 131 weeks

PFS was defined as the time in months from the date of first administration of study treatment until the first observation of PD or death due to any cause, whichever occurs first, i.e.: (date of first PD or death date of first administration of study treatment +1)/30.4375. Median and 95% CI were calculated using the Kaplan-Meier method. Participants who did not have an observed documented PD or death from any cause were censored at the latest tumor response assessment date. PD: at least a 20% increase in the sum of diameters of target lesions. The sum must also demonstrate an increase of at l

Group	Value	95% CI
Phase 1b: Onvansertib 15 mg/m^2	18	3.7 – NA
Phase 2 Part 1: Onvansertib 15 mg/m^2	6	5.6 – 11.1
Phase 2 Part 2: Onvansertib 15 mg/m^2	8	3.9 – NA
Phase 1b and 2 Total: Onvansertib 15 mg/m^2	8	5.8 – 13.5

All-Treated Analysis Set: Duration of Response (DoR) Secondary · Up to a maximum of 131 weeks

DoR was calculated as the (date of first documented tumor progression or death due to any cause minus date of first documentation of a subsequently confirmed objective response plus 1)/30.4375. Participants who did not have an observed documented PD or death from any cause were censored at the latest tumor response assessment date.

Group	Value	95% CI
Phase 1b: Onvansertib 15 mg/m^2	12	NA – NA
Phase 2 Part 1: Onvansertib 15 mg/m^2	12	3.8 – NA
Phase 2 Part 2: Onvansertib 15 mg/m^2	NA	NA – NA
Phase 1b and 2 Total: Onvansertib 15 mg/m^2	12	7.5 – NA

All-Treated Analysis Set: Overall Survival (OS) Secondary · Up to a maximum of 131 weeks

OS was defined as the time in months from the date of first administration of study treatment until death due to any cause, i.e.: (Date of death date of first administration of study treatment +1)/30.4375. Participants who did not have documented death from any cause were censored at the date they were last known to be alive. OS was added as an endpoint with Protocol Amendment #1, therefore, OS data was only collected from then onward.

Group	Value	95% CI
Phase 1b: Onvansertib 15 mg/m^2	NA	NA – NA
Phase 2 Part 1: Onvansertib 15 mg/m^2	NA	19.7 – NA
Phase 2 Part 2: Onvansertib 15 mg/m^2	NA	14.4 – NA
Phase 1b and 2 Total: Onvansertib 15 mg/m^2	NA	19.7 – NA

All-Treated Analysis Set: Percentage Change in KRAS-mutant Allelic Fraction (MAF) Secondary · Cycle 1 Day 1 and Cycle 2 Day 1 (28-day cycle length)

Blood samples were analyzed for the presence of circulating tumor DNA (ctDNA \[including KRAS mutations\]). KRAS-mutant allelic burden was based on liquid biopsies.

Group	Value	95% CI
Phase 1b: Onvansertib 15 mg/m^2	-85.5857	± 19.44200
Phase 2 Part 1: Onvansertib 15 mg/m^2	-76.2323	± 26.43313
Phase 2 Part 2: Onvansertib 15 mg/m^2	-62.0000	± 33.72414
Phase 1b and 2 Total: Onvansertib 15 mg/m^2	-74.9000	± 27.45740

Phase 2: Observed Plasma Concentration at the End of Each Dosing Interval (Ctrough) of Onvansertib Secondary · Pre-dose on Day 1 of Cycles 1 and 3 (28-day cycle length)

Plasma pharmacokinetic (PK) parameters for onvansertib were estimated using non-compartmental methods.

Cycle 1 Day 1

Group	Value	95% CI
Phase 2: Onvansertib 15 mg/m^2	0.0000	± 0.0000

Cycle 3 Day 1

Group	Value	95% CI
Phase 2: Onvansertib 15 mg/m^2	0.3406	± 0.34496

All-Treated Analysis Set: ORR by Bevacizumab Used in First-line Treatment Secondary · Up to a maximum of 131 weeks

ORR was defined as the percentage of participants documented to have a confirmed CR or PR using the RECIST v1.1. Two-sided 95% CI was calculated using the exact binomial Clopper-Pearson method. Data are presented by bevacizumab used in first-line treatment yes versus no. CR: disappearance of all target and non-target lesions. Any pathological lymph nodes (whether target or non-target) must have had a reduction in short axis to \< 10 mm. All lymph nodes must have been non-pathological in size (\< 10mm short axis). PR: at least a 30% decrease in the sum of diameters of target lesions, taking a

Group	Value	95% CI
Phase 1b; Bevacizumab Used in First-line Treatment: Onvansertib 15 mg/m^2	42.9	9.9 – 81.6
Phase 2 Part 1; Bevacizumab Used in First-line Treatment: Onvansertib 15 mg/m^2	4.5	0.1 – 22.8
Phase 2 Part 1; Bevacizumab Not Used in First-line Treatment: Onvansertib 15 mg/m^2	72.7	39.0 – 94.0
Phase 2 Part 2; Bevacizumab Used in First-line Treatment: Onvansertib 15 mg/m^2	0	0.0 – 28.5
Phase 2 Part 2; Bevacizumab Not Used in First-line Treatment: Onvansertib 15 mg/m^2	100	15.8 – 100.0
Phase 1b and 2 Total; Bevacizumab Used in First-line Treatment: Onvansertib 15 mg/m^2	10.0	2.8 – 23.7
Phase 1b and 2 Total; Bevacizumab Not Used in First-line Treatment: Onvansertib 15 mg/m^2	76.9	46.2 – 95.0

All-Treated Analysis Set: PFS by Bevacizumab Used in First-line Treatment Secondary · Up to a maximum of 131 weeks

PFS was defined as the time in months from the date of first administration of study treatment until the first observation of PD or death due to any cause, whichever occurs first, i.e.: (date of first PD or death date of first administration of study treatment +1)/30.4375. Median and 95% CI were calculated using the Kaplan-Meier method. Participants who did not have an observed documented PD or death from any cause were censored at the latest tumor response assessment date. Data are presented by bevacizumab used in first-line treatment yes versus no. PD: at least a 20% increase in the sum of

Group	Value	95% CI
Phase 1b; Bevacizumab Used in First-line Treatment: Onvansertib 15 mg/m^2	18	3.7 – NA
Phase 2 Part 1; Bevacizumab Used in First-line Treatment: Onvansertib 15 mg/m^2	6	3.6 – 6.1
Phase 2 Part 1; Bevacizumab Not Used in First-line Treatment: Onvansertib 15 mg/m^2	15	9.5 – NA
Phase 2 Part 2; Bevacizumab Used in First-line Treatment: Onvansertib 15 mg/m^2	8	3.7 – NA
Phase 2 Part 2; Bevacizumab Not Used in First-line Treatment: Onvansertib 15 mg/m^2	NA	NA – NA
Phase 1b and 2 Total; Bevacizumab Used in First-line Treatment: Onvansertib 15 mg/m^2	6	5.3 – 8.4
Phase 1b and 2 Total; Bevacizumab Not Used in First-line Treatment: Onvansertib 15 mg/m^2	15	9.5 – NA

Adverse events — posted to ClinicalTrials.gov

Time frame: Up to a maximum of 131 weeks. Reporting threshold: 0%. Adverse-event reports describe events observed during the trial — not all are caused by the drug.

Phase 1b: Onvansertib 12 mg/m^2

Serious: 2/9 (22%)

Deaths: 0/9

Phase 1b: Onvansertib 15 mg/m^2

Serious: 3/7 (43%)

Deaths: 0/7

Phase 1b: Onvansertib 18 mg/m^2

Serious: 1/6 (17%)

Deaths: 0/6

Phase 2: Onvansertib 15 mg/m^2

Serious: 17/46 (37%)

Deaths: 1/46

Serious adverse events (33 terms)

Reaction	System	Phase 1b: Onvansertib 12 m…	Phase 1b: Onvansertib 15 m…	Phase 1b: Onvansertib 18 m…	Phase 2: Onvansertib 15 mg…
Vomiting	Gastrointestinal disorders	—	—	—	—
Dehydration	Metabolism and nutrition disorders	—	—	—	—
Nausea	Gastrointestinal disorders	—	—	—	—
Hepatectomy	Surgical and medical procedures	—	—	—	—
Hydronephrosis	Renal and urinary disorders	—	—	—	—
Abdominal pain	Gastrointestinal disorders	—	—	—	—
Diarrhoea	Gastrointestinal disorders	—	—	—	—
Colitis	Gastrointestinal disorders	—	—	—	—
Constipation	Gastrointestinal disorders	—	—	—	—
Intestinal obstruction	Gastrointestinal disorders	—	—	—	—
Large intestine perforation	Gastrointestinal disorders	—	—	—	—
Small intestinal obstruction	Gastrointestinal disorders	—	—	—	—
Abdominal abscess	Infections and infestations	—	—	—	—
Hepatitis B	Infections and infestations	—	—	—	—
Liver abscess	Infections and infestations	—	—	—	—
Pyelonephritis	Infections and infestations	—	—	—	—
Sepsis	Infections and infestations	—	—	—	—
Subcutaneous abscess	Infections and infestations	—	—	—	—
Urosepsis	Infections and infestations	—	—	—	—
Sigmoidectomy	Surgical and medical procedures	—	—	—	—
Fatigue	General disorders	—	—	—	—
Systemic inflammatory response syndrome	General disorders	—	—	—	—
Febrile neutropenia	Blood and lymphatic system disorders	—	—	—	—
Retinal detachment	Eye disorders	—	—	—	—
Hepatic cirrhosis	Hepatobiliary disorders	—	—	—	—

Other adverse events (233 terms — click to expand)

Reaction	System	Phase 1b: Onvansertib 12 m…	Phase 1b: Onvansertib 15 m…	Phase 1b: Onvansertib 18 m…	Phase 2: Onvansertib 15 mg…
Fatigue	General disorders	—	—	—	—
Nausea	Gastrointestinal disorders	—	—	—	—
Diarrhoea	Gastrointestinal disorders	—	—	—	—
Stomatitis	Gastrointestinal disorders	—	—	—	—
Neutrophil count decreased	Investigations	—	—	—	—
Anaemia	Blood and lymphatic system disorders	—	—	—	—
Neutropenia	Blood and lymphatic system disorders	—	—	—	—
Abdominal pain	Gastrointestinal disorders	—	—	—	—
Constipation	Gastrointestinal disorders	—	—	—	—
Hypertension	Vascular disorders	—	—	—	—
Alopecia	Skin and subcutaneous tissue disorders	—	—	—	—
White blood cell count decreased	Investigations	—	—	—	—
Platelet count decreased	Investigations	—	—	—	—
Vomiting	Gastrointestinal disorders	—	—	—	—
Decreased appetite	Metabolism and nutrition disorders	—	—	—	—
Headache	Nervous system disorders	—	—	—	—
Epistaxis	Respiratory, thoracic and mediastinal disorders	—	—	—	—
Weight decreased	Investigations	—	—	—	—
Cough	Respiratory, thoracic and mediastinal disorders	—	—	—	—
Dyspnoea	Respiratory, thoracic and mediastinal disorders	—	—	—	—
Back pain	Musculoskeletal and connective tissue disorders	—	—	—	—
Non-cardiac chest pain	General disorders	—	—	—	—
Aspartate aminotransferase increased	Investigations	—	—	—	—
Dehydration	Metabolism and nutrition disorders	—	—	—	—
Palmar-plantar erythrodysaesthesia syndrome	Skin and subcutaneous tissue disorders	—	—	—	—
Corona virus infection	Infections and infestations	—	—	—	—
Blood alkaline phosphatase increased	Investigations	—	—	—	—
Lymphocyte count decreased	Investigations	—	—	—	—
Leukopenia	Blood and lymphatic system disorders	—	—	—	—
Hypokalaemia	Metabolism and nutrition disorders	—	—	—	—
Peripheral sensory neuropathy	Nervous system disorders	—	—	—	—
Arthralgia	Musculoskeletal and connective tissue disorders	—	—	—	—
Haemorrhoids	Gastrointestinal disorders	—	—	—	—
Pyrexia	General disorders	—	—	—	—
Oedema peripheral	General disorders	—	—	—	—
Blood bicarbonate decreased	Investigations	—	—	—	—
Hypocalcaemia	Metabolism and nutrition disorders	—	—	—	—
Hyponatraemia	Metabolism and nutrition disorders	—	—	—	—
Hypomagnesaemia	Metabolism and nutrition disorders	—	—	—	—
Dysgeusia	Nervous system disorders	—	—	—	—

Most-reported serious reactions: Vomiting, Dehydration, Nausea, Hepatectomy, Hydronephrosis, Abdominal pain, Diarrhoea, Colitis.

Data from ClinicalTrials.gov NCT03829410 adverse events section.

Sponsor's own description

The purpose of the Phase 1b/2 study is to determine the safety and efficacy of Onvansertib, administered orally, daily on Day 1-5 and Day 15-19 of each 28-day cycle, in combination with FOLFIRI + Bevacizumab, as second-line treatment in adult participants who have metastatic colorectal cancer with a KRAS mutation. Participants must have histologically confirmed metastatic and unresectable disease, and previously failed treatment or be intolerant to fluoropyrimidine and oxaliplatin with or without bevacizumab.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

The two sides of chromosomal instability: drivers and brakes in cancer.
Hosea R, Hillary S, Naqvi S, Wu S, et al · · 2024 · cited 102× · PMID 38553459 · DOI 10.1038/s41392-024-01767-7
Harnessing the tumor microenvironment: targeted cancer therapies through modulation of epithelial-mesenchymal transition.
Glaviano A, Lau HS, Carter LM, Lee EHC, et al · · 2025 · cited 90× · PMID 39806516 · DOI 10.1186/s13045-024-01634-6
A new wave of innovations within the DNA damage response.
Li Q, Qian W, Zhang Y, Hu L, et al · · 2023 · cited 85× · PMID 37679326 · DOI 10.1038/s41392-023-01548-8
Targeting <i>KRAS</i> in Cancer: Promising Therapeutic Strategies.
Mustachio LM, Chelariu-Raicu A, Szekvolgyi L, Roszik J. · · 2021 · cited 67× · PMID 33801965 · DOI 10.3390/cancers13061204
Therapeutic Targeting of DNA Damage Response in Cancer.
Choi W, Lee ES. · · 2022 · cited 61× · PMID 35163621 · DOI 10.3390/ijms23031701
KRAS Mutations in Solid Tumors: Characteristics, Current Therapeutic Strategy, and Potential Treatment Exploration.
Yang Y, Zhang H, Huang S, Chu Q. · · 2023 · cited 50× · PMID 36675641 · DOI 10.3390/jcm12020709
Onvansertib in Combination with FOLFIRI and Bevacizumab in Second-Line Treatment of KRAS-Mutant Metastatic Colorectal Cancer: A Phase Ib Clinical Study.
Ahn DH, Barzi A, Ridinger M, Samuëlsz E, et al · · 2024 · cited 46× · PMID 38231047 · DOI 10.1158/1078-0432.ccr-23-3053
New Horizons of Synthetic Lethality in Cancer: Current Development and Future Perspectives.
Previtali V, Bagnolini G, Ciamarone A, Ferrandi G, et al · · 2024 · cited 41× · PMID 38955347 · DOI 10.1021/acs.jmedchem.4c00113

Verify or expand the search:

Other trials of Onvansertib

Trials testing the same drug.

NCT06398587 — Onvansertib in Combination With Gemcitabine and Nab-paclitaxel for the Treatment of Patients With Locally-advanced, Unre · Phase 2 · withdrawn
NCT05549661 — Onvansertib for the Treatment of Recurrent or Refractory Chronic Myelomonocytic Leukemia and Myelodysplastic Syndrome/MP · Phase 1 · recruiting
NCT05593328 — Study of Onvansertib in Combination With FOLFIRI and Bevacizumab Versus FOLFIRI and Bevacizumab for Second Line Treatmen · Phase 2 · completed
NCT05383196 — Onvansertib + Paclitaxel In TNBC · Phase 1, PHASE2 · active not recruiting
NCT05450965 — Study of PLK1 Inhibitor, Onvansertib, in Relapsed Small Cell Lung Cancer · Phase 2 · recruiting

Other recruiting trials for Metastatic Colorectal Cancer

Currently open trials in the same condition.

NCT07416552 — A Study to Investigate CEA-PRIT 2.0 in Participants With Metastatic Colorectal Cancer (mCRC) · Phase 1 · recruiting
NCT07314294 — Phase II Study of EMB-01 in Recurrent/Metastatic Colorectal Cancer Patients · Phase 2 · recruiting
NCT06856837 — - IKF/AIO-QUINTIS - Evaluating Fruquintinib in Combination With Tislelizumab in Microsatellite Stable / Proficient Misma · Phase 2 · recruiting
NCT06959550 — Phase II Study of Anti-PD-1/VEGF Bispecific Antibody Ivonescimab in Patients With Previously Treated Metastatic Colorect · Phase 2 · recruiting
NCT06808685 — Real World Multicenter National Study to Evaluate the Effectiveness and Safety of Biosimilar Bevacizumab Elovie · recruiting

Other Cardiff Oncology trials

Trials by the same sponsor.

NCT05593328 — Study of Onvansertib in Combination With FOLFIRI and Bevacizumab Versus FOLFIRI and Bevacizumab for Second Line Treatmen · Phase 2 · completed
NCT04752696 — Onvansertib in Combination With Nanoliposomal Irinotecan, Leucovorin, and Fluorouracil for Second-Line Treatment of Part · Phase 2 · completed
NCT03414034 — Onvansertib in Combination With Abiraterone and Prednisone in Adult Patients With Metastatic Castration-Resistant Prosta · Phase 2 · completed
NCT03303339 — Onvansertib in Combination With Either Low-dose Cytarabine or Decitabine in Adult Patients With Acute Myeloid Leukemia ( · Phase 1, PHASE2 · completed
NCT04446793 — Expanded Access of Onvansertib With FOLFIRI and Bevacizumab for the Second-Line Treatment of Participants With KRAS-Muta · no longer available

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03829410 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Cardiff Oncology
Last refreshed: 4 March 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03829410.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing